Genaera, Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)

September 10th, 2007 -- Genaera Corporation (NASDAQ: GENR) announced the formation of its Trodusquemine Scientific Advisory Board (the “SAB”), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance on the development of trodusquemine (MSI-1436), the Company’s novel small molecule drug candidate for the treatment of obesity and type 2 diabetes... Genaera's Press Release -